ArticleBMC biology2025
CanCellCap: robust cancer cell capture across tissue types on single-cell RNA-seq data by multi-domain learning.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe advent of single-cell RNA sequencing (scRNA-seq) has provided unprecedented insights into cancer cellular diversity, enabling a comprehensive understanding of cancer at the single-cell level. However, identifying cancer cells remains challenging due to gene expression variability caused by tumor or tissue heterogeneity, which negatively impacts generalization and robustness.
resultsWe propose CanCellCap, a multi-domain learning framework, to identify cancer cells in scRNA-seq data suitable for all tissues, cancers, and sequencing platforms. Integrating domain adversarial learning and Mixture of Experts, CanCellCap is able to simultaneously extract common and specific patterns in gene expression profiles across different tissues for cancer or normal cells. Moreover, the masking-reconstruction strategy enables CanCellCap to cope with scRNA-seq data from different sequencing platforms. CanCellCap achieves 0.977 average accuracy in cancer cell identification across 13 tissue types, 23 cancer types, and 7 sequencing platforms. It outperforms five state-of-the-art methods on 33 benchmark datasets. Notably, CanCellCap maintains high performance on unseen cancer types, tissue types, and even across species, highlighting its effectiveness in challenging scenarios. It also excels in spatial transcriptomics by accurately identifying cancer spots. Furthermore, CanCellCap demonstrates strong computational efficiency, completing inference on 100,000 cells in a few minutes. In addition, interpretability analyses reveal critical biomarkers and pathways, offering valuable biological insights.
conclusionsCanCellCap provides a robust and accurate framework for identifying cancer cells across diverse platforms, tissue types, and cancer types. Its strong generalization to unseen cancers, tissues, and even species, combined with its adaptability to spatial transcriptomics data, underscores its versatility for both research and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.